SPRY2 and response to FOLFOX/CAPOX in metastatic KRAS mutated colorectal cancer

被引：0
|
作者：
Montal, R. [1 ]
Merche, M. -V. [1 ]
Anta, B. [2 ]
Martinez, N. [2 ]
Santos, C. [1 ,3 ]
Sanjuan, X. [4 ]
Paules, M. J. [5 ]
Perez Martin, F. J. [6 ]
Azuara, D. [3 ]
Salazar, R. [1 ,3 ]
Rojas, J. M. [2 ]
机构：
[1] Inst Catala Oncol IDIBELL, Dept Med Oncol, Lhospitalet De Llobregat, Spain
[2] Inst Salud Carlos III UFIEC, Majadahonda, Spain
[3] Inst Catala Oncol IDIBELL, Translat Res Lab, Lhospitalet De Llobregat, Spain
[4] Hosp Univ Bellvitge IDIBELL, Dept Pathol, Lhospitalet De Llobregat, Spain
[5] HUB, IDIBELL, Interdisciplinary Comm Esophagogastr Tumours, Lhospitalet De Llobregat, Spain
[6] Inst Catala Oncol ICO LHospitalet, IDIBELL, Clin Res Unit, Lhospitalet De Llobregat, Spain
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv233.193
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-195
引用
收藏
页数：1
相关论文
共 50 条
  • [31] KRAS mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
    Spindler, K.
    Appelt, A. L.
    Pallisgaard, N.
    Andersen, R. F.
    Jakobsen, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S11 - S11
  • [32] Targeted sequencing identified JAK/STAT pathway alteration in KRAS mutated metastatic colorectal cancer
    Chen, Shu-Jen
    Thiam, Tan Kien
    Liu, Shang-Yun
    Chen, Hua-Chien
    Chung, David
    Hsu, Hung-Chih
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Polo-like Kinase 1 Inhibition in KRAS-Mutated Metastatic Colorectal Cancer
    Stebbing, Justin
    Bullock, Andrea J.
    CLINICAL CANCER RESEARCH, 2024, 30 (10) : 2005 - 2007
  • [34] Role of MSI and DCC status to predict response to FOLFOX in metastatic colorectal cancer
    Bennamoun, M.
    Schischmanoff, O.
    Martin, A.
    Mariani, P.
    Koon, L. Ah
    Morere, J.
    Guetz, G. Des
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy
    Sharma, Neelesh
    Saifo, Maher
    Tamaskar, Ila R.
    Bhuvaneswari, Ramkumar
    Mashtare, Terry
    Fakih, Marwan
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2010, 1 (02) : 90 - 96
  • [36] KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
    K G Spindler
    A L Appelt
    N Pallisgaard
    R F Andersen
    A Jakobsen
    British Journal of Cancer, 2013, 109 : 3067 - 3072
  • [37] KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
    Spindler, K. G.
    Appelt, A. L.
    Pallisgaard, N.
    Andersen, R. F.
    Jakobsen, A.
    BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 3067 - 3072
  • [38] Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients
    Lavacchi, Daniele
    Gelmini, Stefania
    Calabri, Adele
    Rossi, Gemma
    Simi, Lisa
    Caliman, Enrico
    Mancini, Irene
    Salvianti, Francesca
    Petroni, Giulia
    Guidolin, Alessia
    Scolari, Federico
    Messerini, Luca
    Pillozzi, Serena
    Pinzani, Pamela
    Antonuzzo, Lorenzo
    HELIYON, 2023, 9 (11)
  • [39] KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary
    Vauthey, J-N
    Kopetz, S.
    Aloia, T. A.
    Andreou, A.
    BRITISH JOURNAL OF CANCER, 2012, 107 (08) : 1442 - 1443
  • [40] KRAS inhibition in metastatic colorectal cancer: An update
    Nusrat, Maliha
    Yaeger, Rona
    CURRENT OPINION IN PHARMACOLOGY, 2023, 68
12345